Daniel Hamstra, MD, PhD, on Prostate Cancer: Decreasing Rectal Toxicity
2016 ASTRO Annual Meeting
Daniel A. Hamstra, MD, PhD, of Texas Oncology, discusses phase III findings on the use of an absorbable hydrogel spacer designed to decrease rectal toxicity and improve bowel quality of life for patients with prostate cancer. (Abstract LBA-6)
Bruce D. Minsky, MD, of The University of Texas MD Anderson Cancer Center and Chairman of the ASTRO Board, discusses top papers presented at this year’s Annual Meeting.
Richard T. Hoppe, MD, of Stanford University, summarizes a session on improving outcomes by enhancing old and new indications in follicular lymphoma and Hodgkin lymphoma. (Scientific Session 5)
Takeshi Kodaira, MD, PhD, of Aichi Cancer Center Hospital, discusses the final analysis of a randomized phase III trial of accelerated vs conventional fractionation radiotherapy for glottic cancer of T1-2N0M0. (Abstract LBA-8)
Douglas W. Arthur, MD, of Virginia Commonwealth University, discusses the 3-year efficacy report from a phase II study of repeat breast-preserving surgery and 3D conformal partial breast reirradiation for in-breast recurrence. (Abstract LBA-10)
Brian Kavanagh, MD, MPH, of the University of Colorado at Denver and ASTRO’s incoming President, discuss his goals for the Society in 2017.